LGVN vs. LXEO, VTYX, ANIX, SNTI, ZURA, ELUT, CLLS, CLYM, IZTC, and OCX
Should you be buying Longeveron stock or one of its competitors? The main competitors of Longeveron include Lexeo Therapeutics (LXEO), Ventyx Biosciences (VTYX), Anixa Biosciences (ANIX), Senti Biosciences (SNTI), Zura Bio (ZURA), Elutia (ELUT), Cellectis (CLLS), Climb Bio (CLYM), Invizyne Technologies (IZTC), and OncoCyte (OCX). These companies are all part of the "pharmaceutical products" industry.
Longeveron vs.
Longeveron (NASDAQ:LGVN) and Lexeo Therapeutics (NASDAQ:LXEO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership, community ranking and risk.
Longeveron has higher revenue and earnings than Lexeo Therapeutics. Lexeo Therapeutics is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks.
In the previous week, Lexeo Therapeutics had 9 more articles in the media than Longeveron. MarketBeat recorded 17 mentions for Lexeo Therapeutics and 8 mentions for Longeveron. Lexeo Therapeutics' average media sentiment score of 0.45 beat Longeveron's score of 0.25 indicating that Lexeo Therapeutics is being referred to more favorably in the news media.
Longeveron has a beta of 0.38, indicating that its stock price is 62% less volatile than the S&P 500. Comparatively, Lexeo Therapeutics has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500.
Lexeo Therapeutics received 10 more outperform votes than Longeveron when rated by MarketBeat users. Likewise, 100.00% of users gave Lexeo Therapeutics an outperform vote while only 94.74% of users gave Longeveron an outperform vote.
Longeveron presently has a consensus price target of $8.67, indicating a potential upside of 546.77%. Lexeo Therapeutics has a consensus price target of $20.20, indicating a potential upside of 599.45%. Given Lexeo Therapeutics' higher possible upside, analysts plainly believe Lexeo Therapeutics is more favorable than Longeveron.
10.0% of Longeveron shares are owned by institutional investors. Comparatively, 60.7% of Lexeo Therapeutics shares are owned by institutional investors. 19.1% of Longeveron shares are owned by insiders. Comparatively, 4.5% of Lexeo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Lexeo Therapeutics has a net margin of 0.00% compared to Longeveron's net margin of -967.49%. Lexeo Therapeutics' return on equity of -57.66% beat Longeveron's return on equity.
Summary
Lexeo Therapeutics beats Longeveron on 13 of the 18 factors compared between the two stocks.
Get Longeveron News Delivered to You Automatically
Sign up to receive the latest news and ratings for LGVN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Longeveron Competitors List
Related Companies and Tools
This page (NASDAQ:LGVN) was last updated on 5/23/2025 by MarketBeat.com Staff
Buy LGVN Stock Free LGVN Stock Alerts